Last reviewed · How we verify
Arbaclofen Placarbil SR
At a glance
| Generic name | Arbaclofen Placarbil SR |
|---|---|
| Sponsor | Indivior Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD (PHASE2)
- A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury (PHASE2)
- A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers (PHASE1)
- A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arbaclofen Placarbil SR CI brief — competitive landscape report
- Arbaclofen Placarbil SR updates RSS · CI watch RSS
- Indivior Inc. portfolio CI